Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
curcumin + simvastatin is a combination pharmacological treatment being evaluated for the management of periodontal defects. It consists of simvastatin, a chemical modification of lovastatin that acts as an HMG-CoA reductase inhibitor, and curcumin, the primary active constituent of turmeric. Simvastatin is included for its anti-inflammatory effects and its ability to inhibit bone resorption while stimulating bone formation. Curcumin provides complementary anti-inflammatory, antioxidant, and antimicrobial properties, targeting both the bacterial pathogens and the host's inflammatory response. This combination is typically formulated as a paste for local application following procedures such as EDTA root surface etching and open flap debridement in patients with stage II-III periodontitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin + simvastatin.